Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World
Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to evaluate the efficacy, safety and tolerability of a
medication, ledipasvir/sofosbuvir (LDV/SOF), used to treat individuals with chronic hepatitis
C virus (HCV) in Rwandan adults. A sub-cohort of participants will have limited laboratory
monitoring to determine the minimum laboratory tests necessary.
Phase:
Phase 4
Details
Lead Sponsor:
Partners in Health
Treatments:
Antiviral Agents Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir